Login to Your Account



GW Pharma's Sativex Performs Well in MS Spasticity Study

By Nuala Moran
Staff Writer

Wednesday, August 14, 2013

LONDON – GW Pharma plc delivered positive results in a UK Phase III postmarketing study of Sativex, which will provide ballast for the launch of the cannabis-based product as a treatment for spasticity caused by multiple sclerosis in national markets across Europe and the Middle East.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription